How far is too far?
The Challenge
People living in remote areas could benefit from improved access to first trimester medication abortion care (mifepristone and misoprostol). Current guidelines limit this service to patients living near emergency services, which may not be necessary. Clearer guidance is needed to help providers decide when it is safe to offer care locally and when patients should travel to access care closer to emergency services.
The Question
In this study, we address a critical gap in abortion guidelines worldwide. We are partnering with researchers from Canada, Scotland, Sweden, and Australia to answer one key question:
How far from a facility capable of blood transfusion and emergency surgery can first trimester medication abortion be safely provided?
The Project
This international study involves multiples methods and aims. You can read a brief summary about the broader study here. At the Reproductive Choices Lab, we specifically aim to understand, what are the abortion experiences of remote residents and the healthcare providers who provide abortion care for remote communities?
To answer this question, we are conducting one-on-one interviews to understand perspectives, approaches, and experiences of first trimester abortion care in remote areas. We also provide leadership in guiding our international partners to address the same question. Our results will inform clinical guidelines, decision supports, and community resources for accessing abortion services.
Who can participate?
Residents of remote communities who have (1) considered or accessed an abortion, OR 2) be interested to share their perspectives on accessing abortion services if needed in the future.
Healthcare providers who provide abortion care (medication or procedural) to remote residents.
If you are interested in participating, email Madeleine by following the button below.
This project is funded by the Canadian Institute of Health Research.